Navigation Links
YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
Date:12/17/2009

- Therapure Biopharma to perform fill/finish of nimotuzumab -

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM). Under the terms of the agreement, Therapure will formulate and fill nimotuzumab into sterile vials in their aseptic GMP certified and Health Canada licensed fill suite in Mississauga, Canada. The facility is built to FDA, EMEA, MHRA and Health Canada standards. The final product will be utilized by YM BioSciences and its licensees, Daiichi Sankyo in Japan, Kuhnil in South Korea, and Oncoscience AG in Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global clinical trials.

Nimotuzumab is a humanized monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), the well-validated oncology target. Nimotuzumab is currently being evaluated in 32 clinical studies worldwide in numerous indications, including multiple stages of non-small-cell lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, gastric cancer and head & neck cancer. Three Phase III trials and eight Phase II trials of those 32 are being conducted between YM and its four licensees. Nimotuzumab has been approved for marketing in 23 countries including Argentina, Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal antibodies are expected to approximate $2 billion.

"We have been very pleased with the performance of nimotuzumab during our on-going clinical development program advancing it towa
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
5. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
6. Cell Biosciences Acquires Protein Forest
7. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
8. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
11. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 05, 2015 Exotic Automation ... announces the launch of http://www.cng.exoticautomation.com , an ... a convenient way to purchase genuine OEM replacement ... , The new website provides owners of ... direct access to high performance products for their ...
(Date:5/5/2015)... Synedgen Inc. is pleased to announce the appointment ... Dr. Nguyen brings to Synedgen critical regulatory expertise and ... it moves forward in the FDA regulatory processes for ... Dr. Nguyen will lead the management of nonclinical studies ... must be completed in order to initiate human clinical ...
(Date:5/4/2015)... , May 4, 2015 Tobira ... focused on the development and commercialization of novel ... the completion of its merger with Regado Biosciences, ... with the closing of the merger, Tobira raised ... of new investors and all current Tobira institutional ...
(Date:5/4/2015)... -- GliaCure, a privately-held biotechnology company focused on ... neuropsychiatric disorders based on glial targets, announced that ... a Phase 1b clinical trial of its lead ... potential disease-modifying treatment. GliaCure,s innovative approach to treating ... promotes the clearance of amyloid and stimulates anti-inflammatory ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2Synedgen Announces the Appointment of Regulatory Affairs Manager 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2
... A new hand-held medical device will help UK athletes ... upcoming sporting competitions. UK Sport, the UK,s high performance ... first organisation to use cutting edge technology developed by ... Elite athletes will be able to monitor various proteins ...
... MOUNTAIN VIEW, Calif., Dec. 9, 2010 The ... of rejuvenation biotechnologies in addressing age-related disease. This ... donation to SENS Foundation, a California-based non-profit organization ... access to rejuvenation biotechnologies which comprehensively address age-related ...
... ("China-Biotics" or "the Company"), (Nasdaq: CHBT ) ... in China, today announced that it has redeemed $25 ... for cash two days before the December 11, 2010 ... originally issued on December 11, 2007. The redemption price ...
Cached Biology Technology:Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3Internet Entrepreneur Jason Hope Pledges Half a Million Dollars to SENS Foundation 2Internet Entrepreneur Jason Hope Pledges Half a Million Dollars to SENS Foundation 3China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 2China-Biotics Announces Redemption of $25 million in Senior Convertible Notes 3
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... To arrange for an interview with a researcher, please contact the ... each tip. For more information on ORNL and its research and ... you have a general media-related question or comment, you can send ... Stride right . . . People recovering from ...
... A new analysis of the extinction of woolly mammoths ... that they may have fallen victim to the same type ... being caused today by the global decline of predators such ... the cascading events were originally begun by human disruption of ...
... Inc. (TSX-V: IOT), a pioneer in the field of ... $900,000 from Agriculture and Agri-Food Canada to facilitate the ... and plant spray designed to protect crops against both ... increase crop yields and improve product quality while minimizing ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 2Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 2'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 4
... variety of solvent vapors that can contaminate and ... (GCF400) allows for the collection of liquid into ... cooling time minimizes waiting period., , Easy ... , -50?C Temerature for ...
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
Biology Products: